In vitro experimental study of gene therapy for ovarian cancer with thymidine kinase gene of herpes simplex virus mediated by a non-viral GE7 delivery system
- VernacularTitle:非病毒载体介导Ⅰ型单纯疱疹病毒胸腺嘧啶核苷激酶基因治疗卵巢癌的体外研究
- Author:
Xiaojun LIU
;
Congjian XU
;
Zhijun JIN
;
Yan LIU
;
Feihan DAI
;
Junsong HAN
;
Peikun TIAN
;
Jianren GU
- Publication Type:Journal Article
- Keywords:
Ovarian neoplasms;
Gene therapy;
Herpesvirus 1, human;
Thymidine kinase
- From:
Chinese Journal of Obstetrics and Gynecology
2000;0(10):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate gene transfer efficiency of a novel target non-viral vector GE7 and effects of herpes simplex virus thymidine kinase (HSV 1-tk)/ganciclovir(GCV) mediated by it in vitro. Methods The epidermal growth factor receptor (EGF-R) target gene delivery system GE7 was constructed.Human ovarian cancer cell line CAOV3 was transfected in vitro with ?-galactosidase(?-gal) as reporter gene and HSV 1-tk gene as therapeutic gene using this gene delivery system.By means of the assay of X-gal staining, Northern blotting, cell growth-inhibiting curve and so on,the transferring efficiency of exogenous genes and killing effects are observed. Results It showed that gene transfer efficiency is over 80%.When 10 mg/L GCV was put into ovarian cells transfected with HSV 1-tk gene, 95% of cells were killed, and the apoptosis ratio reached up to 30. Conclusions The GE7 gene delivery system is an effective and safe delivery system.GE7/ HSV 1-tk /GCV therapeutic gene system is appraising for ovarian cancer.
